The deal is Merck’s largest since 2015, when it spent $17bn on acquiring Sigma-Aldrich, also a life sciences specialist.

The deal, Merck's largest since its Sigma-Aldrich buyout, expands its presence in proteins, spatial biology, and cell and gene therapy ...

Bio-Techne stock jumps, with Germany’s Merck KGaA buying the company at a 24% premium.

View Bio-Techne Corporation TECH stock quote prices, financial information, real-time forecasts, and company news from CNN.

June 25 (Reuters) - Merck KGaA has agreed to acquire biotech firm Bio-Techne Corp for $11.3 billion, the German science and healthcare firm said in a statement on Thursday. Shares of Bio-Techne rose ...

A German company that provides products and services that accelerate drug development and manufacturing is set to acquire the Minneapolis-based group Bio-Techne, according to a news release posted ...

Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions to its R&D Systems™ AI-Engineered ...

German drugmaker Merck ​KGaA said on Thursday it will acquire U.S. biotech firm Bio-Techne for $11.3 billion, its largest deal in over a decade.

Merck KGaA agreed to buy Bio-Techne Corporation for $11.3 billion to bolster its life-science business, marking the German pharma and technology group’s biggest acquisition in more than a decade.

Q1 beat and Bio-Techne deal drive upside, but valuation looks full. Read here for a detailed investment analysis.

Hollow Brook Wealth Management sold its entire position in Bio-Techne -- 174,677 shares -- during the fourth quarter of 2025, for an estimated $10.7 million based on quarterly average pricing. The ...